Simcor is approved for use along with diet to lower levels of elevated total cholesterol, low-density lipoprotein (LDL) ‘bad’ cholesterol and triglycerides, and to raise high-density lipoprotein (HDL) ‘good’ cholesterol in patients with complex lipid disease when treatment with simvastatin or Niaspan monotherapies are not considered adequate.
Eugene Sun, vice president of global clinical development for Abbott, said: “With Simcor, doctors now have a new option for helping patients reach their LDL and HDL cholesterol treatment goals with a combination of two proven therapies.”